Direct-acting antivirals
61 articles
Beyond Intellectual Property: Why Is Generic Treatment for HCV Still So Hard to Get
An article in 2023 issue of TAGline explores how to reimagine HCV elimination strategies now that intellectual property is no longer restricting access to generic cures. More
Antiviral Therapy Reduces Risk of Cardiovascular Outcomes in Patients with HCV
Use of antiviral therapy is linked to a decreased risk of multiple cardiovascular outcomes and mortality compared to patients not using antiviral therapy. More
Long-Term Benefit of DAAs on Gut Dysbiosis and Microbial Translocation
Long-term benefit of DAAs on gut dysbiosis and microbial translocation in HCV-infected patients with and without HIV coinfection More
Public Reimbursement Policies in Canada for Direct-Acting Antiviral Treatment for Hepatitis C
Public reimbursement policies in Canada for direct-acting antiviral treatment of hepatitis C virus infection: A descriptive study More
Direct-Acting Antivirals Prove Long-Acting on HCV Infection after Liver Transplant
Long-term follow-up of direct-acting antiviral treatment of HCV infection after liver transplant shows persistent improvement in hepatic function, fibrosis, and survival rate. More
